Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (EMPIRE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02222948 |
|
Recruitment Status :
Terminated
(Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.)
First Posted : August 22, 2014
Last Update Posted : December 21, 2016
|
Sponsor:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | April 2016 |
| Actual Study Completion Date : | July 2016 |
| Certification/Extension First Submitted : | December 20, 2016 |